EMA / EU medicines lifecycle compliance
Talk to IGXGxP responsibilities cross quality, manufacturing, clinical, safety, regulatory and partner organisations. The mandate becomes urgent when an audit, regulatory change, incident or assurance request requires the organisation to prove how an obligation operates in practice.
Requirements, SOPs, processes, systems, controls and evidence stay aligned across the product lifecycle when they are traced from obligation through process to retained evidence.
EU pharmaceutical organisations maintain compliant, inspection-ready processes across GMP, GDP, GCP, GLP and good pharmacovigilance practices. A connected view keeps them consistent as products and regulations change.
Create a connected GxP process architecture and controlled execution path. Change and assurance are managed as connected operational work, with accountable remediation and evidence available by design.
- Greater consistency, faster inspection response and safer regulatory change
- Faster regulatory impact assessment
- Earlier detection of control and evidence gaps
- Reduced audit and inspection preparation
- Defensible traceability from duty to execution
EMA states that organisations across medicine development, manufacture, marketing and distribution are responsible for compliance with applicable EU pharmaceutical standards.
EMA: Compliance Overview
EMA describes GMP as the minimum standard for medicines manufacturing processes and coordinates inspections to verify and harmonise compliance across the EU.
EMA: Good manufacturing practice